Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16360479 | 0.86 | — | — | |
| SCHEMBL16300276 | 0.84 | ALDH1A1 (0.32) | BRD4PDK2MAPTL3MBTL1NSD2 | |
| SCHEMBL4568665 | 0.84 | ALDH1A1 (0.32) | BRD4PDK2MAPTL3MBTL1NSD2 | |
| SCHEMBL10267942 | 0.84 | PDK2 (0.37) | PDK2MAPTL3MBTL1TDP1 | |
| SCHEMBL4568640 | 0.83 | — | — | |
| SCHEMBL4568682 | 0.83 | — | — | |
| SCHEMBL10262645 | 0.82 | CFTR (0.36) | PDK2MAPTL3MBTL1LMNAMEN1 | |
| SCHEMBL4568677 | 0.81 | — | — | |
| SCHEMBL16360481 | 0.81 | NPSR1 (0.31) | BRD4MAPTMEN1KMT2A | |
| SCHEMBL10261936 | 0.81 | PDK2 (0.37) | PDK2MAPTL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | ALK 1267/4885BRD4 509/4885PDK2 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.